https://www.selleckchem.com/pr....oducts/combretastati
6%) adenocarcinomas, 23 (42.6%) SCC, 2 (3.70%) SCLC. SCLC was significantly more prevalent in patients with pure COPD (p less then 0.05) than in those with ACO. Differences between the numbers of other histological types of lung cancer and the numbers of driver mutations in the 2 groups of patients were not significant. CONCLUSION The differences in the rate of lung cancer and prevalence of EGFR driver mutations between the patients with pure COPD and those with ACO were not significant.PURPOSE Cancer stem cells (CSCs) play an
Mi piace
Commento
Condividi
